On March 25, 2025 KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, reported the upcoming presentation of a poster at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL (Press release, KaliVir Immunotherapeutics, MAR 25, 2025, View Source [SID1234651442]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will focus on the company’s clinical oncolytic immunotherapy, VET3-TGI, for patients with incurable, advanced solid tumors. VET3-TGI is a novel oncolytic immunotherapy which is designed to systemically target and selectively kill tumor cells while also expressing an immuno-stimulatory transgene payload consisting of interleukin-12 and a TGFbeta inhibitor.

Details on the poster presentation are below:

Presentation Title: Mechanisms of synergy between TGF-beta inhibitor and IL12 expression from the systemically deliverable clinical oncolytic immunotherapy VET3-TGI
Abstract Number: 484
Session Date & Time: Sunday, April 27, 2025; 2-5 pm
Presenter: Stephen Thorne, PhD, Co-founder and Chief Scientific Officer, KaliVir Immunotherapeutics